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Many psychiatric and neurological disorders are
characterized by learning and memory deficits, for
which cognitive enhancement is considered a valid
treatment strategy. The N-methyl-D-aspartate re-
ceptor (NMDAR) is a prime target for the develop-
ment of cognitive enhancers because of its funda-
mental role in learning and memory. In particular,
the NMDAR subunit NR2B improves synaptic plas-
ticity and memory when overexpressed in neurons.
However, NR2B regulation is not well understood
and no therapies potentiating NMDAR function
have been developed. Here, we show that serine
1116 of NR2B is phosphorylated by cyclin-depen-
dent kinase 5 (Cdk5). Cdk5-dependent NR2B phos-
phorylation is regulated by neuronal activity and
controls the receptor’s cell surface expression. Dis-
rupting NR2B-Cdk5 interaction via a small interfering
peptide (siP) increases NR2B surface levels, facili-
tates synaptic transmission, and improves memory
formation in vivo. Our results reveal a regulatory
mechanism critical to NR2B function that can be tar-
geted for the development of cognitive enhancers.
INTRODUCTION
N-methyl-D-aspartate receptors (NMDARs) are ionotropic gluta-
mate receptors that exhibit broad expression within the nervous
system and are critically involved in neuronal processes such as
synaptic plasticity and learning and memory (Bliss and Colling-
ridge, 1993;Martin et al., 2000). Functional NMDARs are obligate
heterotetrameric complexes formed by two glycine-binding
GluN1 subunits assembled with two of several isoforms of the
glutamate-binding GluN2 (A, B, C, or D subtypes) or glycine-
binding GluN3 (A or B subtypes) (Cull-Candy and Leszkiewicz,
2004; Dingledine et al., 1999). The biophysical properties of1070 Neuron 81, 1070–1083, March 5, 2014 ª2014 Elsevier Inc.NMDARs are dependent on their subunit composition (Morrisett,
1997). Indeed, NMDAR subunit composition varies greatly
between different synapses and neurons, as well as during
neuronal development (Monyer et al., 1994; Sheng et al.,
1994). Therefore, precise spatiotemporal regulation of NMDAR
subunit expression, composition, trafficking, and localization is
critical for proper neuronal function.
Brain regions involved in mnemonic functions rely predomi-
nantly upon GluN2A (NR2A) and GluN2B (NR2B) subunit-
containing NMDARs. During postnatal development, NR2B
expression steadily decreases, whereas NR2A levels rise. Com-
pared to NR2A-containing NMDARs, receptors that include
NR2B inactivatemoreslowly and, consequently, havebeenasso-
ciatedwith increased levels of synaptic plasticity (Cull-Candy and
Leszkiewicz, 2004; Lau and Zukin, 2007). Consistently, upregula-
tion of NR2B expression in mice improves synaptic plasticity and
memory formation (Crair and Malenka, 1995; Tang et al., 1999).
Numerous animal models that feature elevated NR2B levels via
altered synthesis, transport, or degradation exhibit improved
synaptic plasticity and memory (Lee and Silva, 2009). Hence,
targeting NR2B and its regulatory machinery has been singled
out as an attractive approach for cognitive enhancement (Bibb
et al., 2010; Collingridge et al., 2013).
One possible strategy to increase NR2B levels involves induc-
tion of its de novo synthesis, for example, via cAMP response
element (CRE)-mediated gene expression or chromatin remod-
eling (Fujita et al., 2012; Jiang et al., 2010; Myers et al., 1999).
Alternative targets include transport or degradation of NR2B
via its coupling to distinct intracellular signaling pathways
(Hawasli et al., 2007; Yin et al., 2011). The molecular machinery
regulating trafficking, subcellular localization, and degradation of
NMDAR subunits is not yet well understood, but it has been
recognized that phosphorylation of NMDAR subunits including
NR2B is important for the regulation of such processes (Chen
and Roche, 2007; Ma and Jan, 2002; Wenthold et al., 2003).
One protein kinase implicated in the metabolism of NR2B is
Cdk5 (Cyclin-dependent kinase 5), although no direct phos-
phorylation of NR2B by Cdk5 has been reported (Hawasli
et al., 2007). Cdk5 is a proline-directed serine/threonine kinase
that is activated upon interaction with the neuron-specific
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implicated in numerous CNS processes, including cortical layer
formation, neurotransmission, and mnemonic functions (Angelo
et al., 2006). Accordingly, a previous study showed that Cdk5
conditional knockout (cKO) mice have improved synaptic plas-
ticity and learning and memory via regulation of NR2B degrada-
tion by calpain (Hawasli et al., 2007). Interestingly, transgenic
mice overexpressing the truncated Cdk5 activator p25 also
exhibit enhanced plasticity and memory formation (Angelo
et al., 2003, 2006; Fischer et al., 2005), suggesting that reduced
Cdk5 expression or displacement from physiological substrates
potentiates synaptic remodeling processes. Despite these
results indicating a close mechanistic relationship between
NR2B and Cdk5 in the control of mnemonic functions, the under-
lying molecular processes remain unknown.
Here we show that Cdk5 directly phosphorylates NR2B at
Ser1116 and that the phosphorylation state of this serine residue
is specifically regulated by physiological neuronal activity. Cdk5-
dependent Ser1116 phosphorylation prevents cell surface
expression of NR2B-containing NMDAR and thus attenuates
synaptic transmission. Disrupting the Cdk5-mediated regulation
of NR2B via small interfering peptides (siPs) to block protein-
protein interactions reduces this phosphorylation, increases
NR2B surface levels, facilitates neurotransmission, and im-
proves hippocampus-dependent learning and memory, sug-
gesting that this regulatory mechanismmay indeed be a suitable
target for the development of cognitive enhancers.
RESULTS
Cdk5 Phosphorylates NR2B at Ser1116 and Controls
Surface Level Expression
Cdk5 has been previously shown to contribute to synaptic
plasticity and memory formation through its control of NR2B
(GluR2B) levels via calpain-mediated degradation (Hawasli
et al., 2007). Because Cdk5 directly associates with this recep-
tor, we investigated whether it could phosphorylate NR2B. To
identify novel Cdk5 phosphorylation sites, we employed a
PhosphoScan approach utilizing antibody-based enrichment of
phospho-peptides from mouse brain with a phospho-specific
Cdk5 substrate antibody followed by tandem mass spectrom-
etry (Rush et al., 2005). This approach identified Ser1116 within
the cytoplasmic carboxy-terminal of NR2B as a novel Cdk5
phosphorylation site (Figures 1A and 1B). To monitor physio-
logical changes in Ser1116 NR2B phosphorylation, a phos-
phorylation state-specific antibody was generated. The
phospho-Ser1116 (P-S1116) NR2B antibody detected time-
dependent in vitro phosphorylation of recombinant NR2B at
Ser1116 byCdk5 (Figure 1C). Analysis of variousmouse brain re-
gions, namely cortex, hippocampus, cerebellum, and striatum,
further revealed that NR2B is phosphorylated at Ser1116 in vivo
(Figures S1A and S1B available online), indicating that this NR2B
phosphorylation functions broadly throughout the brain. Treat-
ment of acute mouse hippocampal slices with the specific
Cdk5 inhibitor CP681301 caused dose-dependent P-S1116
NR2B reduction (Figure 1D). Moreover, Cdk5 inhibitor-induced
reduction of NR2B phosphorylation at Ser1116 followed a similar
time course as did the reduction of phospho-Thr75 DARPP-32, awell-established Cdk5 substrate (Figure S1C; Bibb et al., 1999).
Finally, P-S1116 NR2B levels were markedly reduced in hippo-
campal lysate of Cdk5 cKOmice (Hawasli et al., 2007) compared
to wild-type (WT) controls (Figure 1E). Together, these results
demonstrate that Ser1116 of NR2B is a physiological Cdk5
phosphorylation site and raise the question of how this post-
translational modification might affect NR2B function.
NMDARs are assembled in the endoplasmic reticulum, traf-
ficked along the secretory pathway, and delivered to the post-
synaptic plasma membrane (Lau and Zukin, 2007; Wenthold
et al., 2003). The molecular machinery underlying NMDAR traf-
ficking and subcellular localization is not yet well characterized,
but it has been recognized that phosphorylation of NMDAR sub-
units including NR2B is important for the regulation of such pro-
cesses (Chen and Roche, 2007; Ma and Jan, 2002; Wenthold
et al., 2003). We noted that Ser1116 of NR2B occurs adjacent
to a putative ER retention signal, RXR (Ma and Jan, 2002) (i.e.,
NH2-.RRRPPRS*PDHK.COOH), and, therefore, investigated
whether Cdk5-dependent phosphorylation of NR2B at Ser1116
affected its subcellular localization. The effect of Cdk5 inhibition
on NR2B cell surface levels was assessed in cultured hippocam-
pal neurons overexpressing NR2B tagged with extracellular
N-terminal green-fluorescent protein (GFP-NR2B). Immunofluo-
rescence staining via anti-GFP antibody thus enabled visualiza-
tion of cell surface GFP-NR2B. Surface-stained GFP-NR2B
exhibited a punctate pattern within dendritic processes (Fig-
ure 1F). Counterlabeling with Homer-1, a marker of postsynaptic
densities (PSDs), demonstrated that the cell surface fraction of
GFP-NR2B localized in proximity to PSDs. Treatment of cultured
hippocampal neurons with the Cdk5 inhibitor CP681301
increased surface expression of NR2B in dendritic processes
approximately 1.3-fold (Figures 1F and 1G), suggesting that
NR2B phosphorylation by Cdk5 modulates NR2B surface levels.
Cdk5-Dependent Regulation of NR2B Function
The abundance of postsynaptic NMDARs is a major determinant
of synaptic plasticity and memory formation (Lee and Silva,
2009; Tang et al., 1999). Thus, blocking Cdk5-dependent reten-
tion of NR2B from the cell surface could be important in regu-
lating its contribution to NMDAR function. To assess this directly,
mouse hippocampal brain slices were treated with either
CP681301 or vehicle (Figure 2A). Cdk5 inhibition increased cell
surface expression of NR2B 3.5-fold with concomitant reduction
in P-S1116 levels to approximately 30% of untreated controls.
The effect appeared specific for NR2B because no changes in
surface levels of NR2A or the AMPA receptor subunit GluR1
were observed (Figures S2A and S2B).
To evaluate the impact of Cdk5-dependent regulation of NR2B
surface levels on physiological function, whole-cell voltage-
clamp recording of synaptically evoked NMDAR-mediated excit-
atory postsynaptic currents (EPSCs) were conducted in CA1
pyramidal neurons of hippocampal slices treated with the
Cdk5 inhibitor CP681301 (Figures 2B–2D). Administration of
CP681301 increased the NMDAR-EPSC amplitude by approxi-
mately 1.5-fold. Furthermore, application of the NR2B-specific
inhibitor ifenprodil had a greater attenuating effect on NMDAR-
EPSCs in CP681301-treated slices (33% reduction) in com-
parison to controls (20% reduction) (Figure 2C), suggestingNeuron 81, 1070–1083, March 5, 2014 ª2014 Elsevier Inc. 1071
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Figure 1. Cdk5 Phosphorylates the NR2B Subunit of the NMDAR at Ser1116 and Regulates Its Cell Surface Expression
(A) Schematic of NR2B indicating domains and motifs.
(B) Positive identification of serine residue 1116 of NR2B as a Cdk5 substrate by LC MS/MS analysis of phospho-peptides immunoprecipitated with phospho-
Cdk substrate antibody.
(C) Time-dependent Ser1116 NR2B phosphorylation (P-S1116) by Cdk5 in vitro detected by quantitative immunoblotting. Quantitated values were normalized to
total NR2B levels.
(D) Dose-dependent reduction of P-S1116 in hippocampal slices incubated with the Cdk5 inhibitor CP681301 (n = 4; *p < 0.05, **p < 0.01, ***p < 0.001;
ANOVA).
(E) Quantitative immunoblot analysis of P-S1116 and total NR2B in hippocampal lysates from Cdk5 cKO andWTmice (n = 4). Loss of Cdk5 in cKO is also shown
(bottom).
(legend continued on next page)
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Figure 2. NR2B Phosphorylation at Ser1116 Regulates NMDAR Function
(A) Increased cell surface NR2B correlates with reduced P-S1116 in hippocampal slices. Levels of cell surface-biotinylated NR2B pulled-down from lysates of
hippocampal slices incubated in the absence (-) or presence (+) of the Cdk5 inhibitor CP681301 are shown with blots and quantitation (n = 4). Prior to pull-down,
lysates were tested for NR2B Load and P-S1116 (bottom).
(B) Effect of Cdk5 inhibition on the NR2B component of NMDAR-EPSCs. Voltage-clamp EPSC recordings of total NMDAR-EPSCs (INMDA) in the absence or
presence of the specific NR2B inhibitor ifenprodil from pyramidal neurons within the hippocampal area CA1 pretreated with vehicle (control) or the Cdk5 inhibitor
CP681301 are shown.
(C and D) Quantitation of NMDAR EPSC recordings showing an increase of ifenprodil-sensitive NR2B component (C) and prolonged decay kinetics (D) of NMDAR
EPSCs in cells incubated in the absence (-) or presence (+) of CP681301 (n = 67).
Data are represented as mean ± SEM. See also Figures S2A and S2B.
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Cdk5 Regulates NR2B in Memory Formationthat the NR2B component of NMDAR-EPSCs was increased by
Cdk5 inhibition. The deactivation kinetics of NMDAR EPSCs was
increased in CP681301-treated slices (170.7 ± 19.4 ms) as
compared to untreated slices (112.1 ± 10.5 ms) (Figure 2D).
This result is consistent with increased NR2B function in
response to CP681301 treatment, because NR2B-containing
NMDARs inactivate more slowly than receptors composed of
other subunits (Cull-Candy and Leszkiewicz, 2004).
Together, these results indicate that Cdk5 regulates the sub-
cellular localization of NMDAR via NR2B phosphorylation at
Ser1116, thereby controlling the level of functional NR2B-
containing NMDARs within the synaptic membrane and modu-
lating NMDAR-mediated synaptic currents.
Regulation of Phospho-Ser1116 NR2B by Glutamatergic
Neurotransmission, Synaptic Plasticity, and Memory
Formation
NMDARs are central to glutamatergic neurotransmission (Bliss
and Collingridge, 1993) and are controlled by complex molecular(F) Inhibition of Cdk5 increases NR2B cell surface levels in hippocampal neuron
(green) and postsynaptic, intraneuronal Homer-1 (red) in hippocampal neurons
depict high magnification of stained dendrites.
(G) Quantification of cell surface GFP-NR2B fluorescence within dendritic proce
Data are represented as mean ± SEM. See also Figure S1.machinery integrating various postsynaptic signaling cascades
(Husi et al., 2000; Newpher and Ehlers, 2008). To better under-
stand how Cdk5-dependent NR2B phosphorylation might be
regulated and contribute to NR2B function in plasticity and
memory formation, the effect of glutamatergic neurotransmis-
sion on P-S1116 NR2B was assessed ex vivo and in vivo.
Treatment of acute mouse hippocampus slices with NMDA
dose-dependently attenuated P-S1116, when normalized to
total NR2B levels (Figure 3A). NMDA treatment also reduced
total NR2B levels, consistent with previous reports of NMDA-
induced, calpain-mediated NR2B degradation (Guttmann
et al., 2001; Hawasli et al., 2007). The ability of NMDA to reduce
P-S1116 in hippocampal slices was attenuated by treatment
with the PP2A/PP1 inhibitor okadaic acid (Figure S2C), indicating
that some of the NMDAR-induced effect on P-S1116 ismediated
via serine/threonine phosphatase activity.
In agreement with the attenuating effect of NMDA on P-S1116,
induction of in vivo long-term potentiation (LTP) in the hippocam-
pal area CA1 also reduced P-S1116. Tetanic stimulation ofs. Top panels show immunofluorescence staining of cell surface GFP-NR2B
treated with vehicle (control) or the Cdk5 inhibitor CP681301. Bottom panels
sses (n = 22–26 cells).
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Figure 3. Phosphorylation of Ser1116 NR2B Is Modulated by Gluta-
matergic Neurotransmission, Synaptic Plasticity, and Memory
Formation
(A) Immunoblots of lysates from NMDA-treated mouse hippocampal slices
probed for P-S1116 and total NR2B (n = 4; *p < 0.05; ANOVA).
(B) Induction of in vivo CA1 LTP in mouse. Sample traces of 5 min periods
before (a) and after (b) high-frequency stimulation (HFS; two trains of 50 pulses
at 100 Hz; 30 s intertrain interval) and LTP induction are shown.
(C) Quantitative immunoblotting of CA1-specific lysates from noninduced (-)
and LTP-induced (+) mice for P-S1116 and total NR2B (n = 5).
(D) Induction of CA1 LTD in mouse hippocampal slices with sample traces of
5 min periods before (a) and after (b) low-frequency stimulation (LFS; 900
stimuli at 1 Hz).
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in vivo caused a significant increase in fEPSP slope (1.4-fold as
compared to baseline) that was maintained for 1 hr poststimulus
(Figure 3B). One hour after LTP induction, P-S1116 was reduced
to approximately 40% of the level in control CA1 lysates (Fig-
ure 3C), demonstrating the physiological regulation of P-S1116
in synaptic plasticity. In contrast, induction of long-term depres-
sion (LTD) did not affect P-S1116 levels (Figures 3D and 3E).
Because excitatory activation of hippocampal NMDAR is integral
to learning and memory (Nakazawa et al., 2004), we also
assessed the involvement of Cdk5-dependent NR2Bphosphory-
lation in mnemonic processes by evaluating P-S1116 levels after
contextual fear conditioning. One hour after training, P-S1116
was reduced in CA1 lysates of fear-conditioned mice to 80% of
the levels in nonshocked context-exposed controls (Figure 3F).
Foot shock in the absence of context had no effect on P-S1116.
Taken together, these results show that NR2B phosphorylation
at Ser1116 is regulated by glutamatergic neurotransmission,
synaptic plasticity, and learning and memory, suggesting an
important role for this signaling mechanism in cognition.
The Protein-Protein Interaction between NR2B and
Cdk5 Can Be Selectively Disrupted by Small Interfering
Peptides
NR2B andCdk5 form a complex both in vitro and in vivo (Hawasli
et al., 2007). To identify physiological protein-protein interaction
sites between NR2B and Cdk5, overlapping eight amino acid
peptide cassettes of the NR2B carboxy-terminal domain were
synthesized on a peptide microarray microchip (Gao et al.,
2004) that was then probed for Cdk5 binding via recombinant
Cdk5 followed by immunodetection with anti-Cdk5 antibody
(Figure 4A). Four motifs exhibiting high Cdk5 binding were iden-
tified by this approach (Figure 4B). To determine whether these
motifs were actual NR2B-Cdk5 interaction sites, peptides corre-
sponding to these motifs were synthesized and tested for their
ability to interfere with NR2B-Cdk5 binding. In this screen,
the peptide corresponding to amino acid residues 1111–1127
(RRPPRSPDHKRYFRDKE; NR2B small interfering peptide
[NR2B siP]) most potently blocked the pull-down of Cdk5 by re-
combinant GST-tagged NR2B in vitro (Figure 4C). Moreover, the
NR2B siP dose-dependently inhibited in vitro phosphorylation of
Ser1116 NR2B by Cdk5 (Figure 4D). In contrast, a scrambled
control peptide (RRRSYFHKEDRPPRDK) did not attenuate
Ser1116 phosphorylation in vitro. Interestingly, the NR2B siP
did not inhibit the in vitro phosphorylation of inhibitor-1 (Fig-
ure S3A), a well-defined Cdk5 substrate (Nguyen et al., 2007),
indicating that the inhibition of Ser1116 NR2B phosphorylation
by NR2B siP was specific.
To further assess the efficacy and consequences of targeting
Cdk5-NR2B protein interactions by small interfering peptides
ex vivo and in vivo, cell-permeabilizing polyarginine or penetratin(E) Quantitative immunoblotting of noninduced (-) and LTD-induced (+) CA1-
specific lysates probed for P-S1116 and total NR2B (n = 5).
(F) Quantitative immunoblots of CA1-specific lysates from contextual fear
conditioned (FC) and control (Context and Foot Shock) mice obtained 1 hr after
training for P-S1116 and total NR2B levels (n = 4–6).
Data are represented as mean ± SEM. See also Figure S2C.
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tides. These tags are commonly used to deliver peptides across
the cell membrane into the cytosol of neurons (Joliot and Pro-
chiantz, 2004).
Consistent with the effects observed in vitro, application of the
NR2B siP to hippocampal slices decreased P-S1116 in a time-
and dose-dependent manner (Figures 4E and S3B). Treatment
with the NR2B siP did not alter levels of NR2B or Cdk5 expres-
sion (Figures 4E and S3B). The specificity of NR2B siP observed
in vitro was retained in vivo; it had no effect on the phosphoryla-
tion state of the well-characterized Cdk5 site Thr75 DARPP-32
(Bibb et al., 1999), but it time-dependently reduced P-S1116 in
acute mouse striatal slices (Figures S3C and S3D). These data
show selective modulation of P-S1116 by siP and also that this
mechanism may be targeted in multiple limbic structures medi-
ating learning and memory. Furthermore, NR2B siP treatment
of hippocampal slices effectively blocked subsequent coimmu-
noprecipitation of Cdk5 and NR2B (Figure 4F), indicating that
siP disrupts Cdk5-NR2B protein-protein interactions. In con-
trast, treatment with scrambled control or the Cdk5 inhibitor
CP681301 did not affect Cdk5-NR2B interactions.
Consistent with our data that Cdk5 regulates NR2B cell sur-
face expression, the siP induced a 3.3-fold increase in NR2B
cell surface levels in hippocampal slices (Figure 4G). Finally,
cell surface GFP-NR2B levels increased 1.5-fold after 30 min
treatment with NR2B siP as compared to control peptide
(S1116A) in primary hippocampal cultures (Figures 4H and 4I).
Thus, Cdk5-NR2B protein-protein interactions can be targeted
in intact brain tissue with NR2B siP, resulting in reduced Cdk5-
dependent phosphorylation of Ser1116 NR2B and appreciable
increases in cell surface expression of the receptor.
Disruption of NR2B-Cdk5 Interaction by NR2B siP
Increases NR2B Function and Facilitates Synaptic
Transmission
Given the efficacy of the NR2B siP in targeting Cdk5-NR2B inter-
actions and increasing NR2B cell surface levels, its impact on
NMDAR-mediated EPSCs was assessed. Treatment of cortical
slices with the NR2B siP produced a 1.8-fold increase in the
NMDA/AMPA EPSC ratio as compared to a scrambled control
peptide (Figure 5A). Moreover, slices incubated with NR2B siP
exhibited a 1.5-fold increase in the ifenprodil-sensitive NR2B
component of NMDAR EPSCs (Figures 5B and 5C), suggesting
that the NR2B siP-induced increase in NMDAR EPSCs is due
to recruitment of additional NR2B-containing NMDAR to the
cell surface.
Given the importance of NR2B in mediating the potentiation of
synaptic transmission during plasticity, we assessed the effects
of NR2B siP on extracellularly recorded field excitatory postsyn-
aptic potentials (fEPSP) in the hippocampal CA3-CA1 pathway.
Treatment of hippocampal slices with NR2B siP rapidly induced
a 1.9-fold increase in fEPSP slope compared to slices infused
with a control peptide (Figures 5D and 5E). Upon washout of
the NR2B siP, fEPSP slopes progressively decreased until they
reached steady-state levels with fEPSP slopes that were 1.6-
fold greater than control treated slices.
To determine whether the NR2B siP-induced changes in hip-
pocampal neurotransmission were due to NR2B, the effects ofthe NR2B siP on basal fEPSPs were assessed in slices coincu-
bated with the specific NR2B antagonist Ro25-6981 (Figures
5F and 5G). Under these conditions, the NR2B siP-mediated in-
crease was blocked. Cdk5 cKOmice lack approximately 70% of
hippocampal Cdk5 and exhibit a reduced threshold for induction
of LTP but have normal baselines for fEPSP fiber volley ampli-
tude (Hawasli et al., 2007). Interestingly, the ability of the NR2B
siP to raise CA1-CA3 fEPSPs was almost absent in Cdk5 cKO
mice with a small (1.2-fold) but still significant increase in fEPSP
slopes (Figures 5F and 5G). Thus the effect of the peptide on syn-
aptic transmission is mediated via NR2B and Cdk5. Together
these results show that NR2B siP selectively disrupts NR2B-
Cdk5 interaction, reduces P-S1116, increases cell surface levels
of NR2B, and facilitates neurotransmission by enhancing NR2B
function.
NR2B siP Improves Learning and Memory
The data presented so far indicate that the subcellular localiza-
tion of NR2B is regulated by Cdk5. Reduction in Cdk5 activity,
as well as disruption of Cdk5-NR2B interaction, consistently
increased NR2B surface levels and facilitated NMDA-mediated
synaptic function. Because previous research has demonstrated
that elevated NR2B function enhances cognitive performance
(Lee and Silva, 2009; Tang et al., 1999), we investigated whether
administration of NR2B siP can improve mnemonic function. For
this purpose, we first established robust in vivo protocols to
deliver cell-penetrating NR2B siP to the appropriate brain re-
gions and test their effect on learning and memory. NMDARs
are required for hippocampus-dependent learning and memory,
such as acquisition of contextual fear memory (Barkus et al.,
2010; Bast et al., 2003). Accordingly, infusion of the selective
NR2B inhibitors Ro25-6981 or ifenprodil into dorsal hippocam-
pus was previously found to impair contextual fear learning,
but not locomotor or anxiety-related behavior (Zhang et al.,
2008). Hence, NR2B siP was infused bilaterally into the CA1
subfield of dorsal hippocampus continuously for 72 hr via mini-
osmotic pumps. Because of the size of the osmotic pump and
the robust behavioral performance, these initial experiments
were performed in rat. Spatiotemporal tracking of fluorescein-
taggedNR2B siP (FITC siP) confirmed correct targeting, continu-
ity of the delivery, and neuronal uptake of the peptide. FITC siP
was specifically detected in dorsal hippocampus at 12, 24, and
72 hr after initiation of pumping. The FITC siP was present in hip-
pocampal area CA1 and labeled the cytoplasmof pyramidal neu-
rons (Figure 6A). After pumping was stopped, intracellular FITC
siP signal was markedly reduced by 6 hr and had largely disap-
peared by 24 hr (Figure S4A).
Within the FITC siP-infused region, P-S1116 was reduced by
approximately 40% compared to FITC scrambled peptide-
infused controls (Figure 6B). Infusion of FITC siP also caused a
3-fold increase inNR2Bsurfaceexpression (Figure6C). Together,
these results validate this approach for the delivery of NR2B siP
into pyramidal neurons of dorsal hippocampus and show that the
NR2B siP induces biochemical and cellular changes in vivo com-
parable to our in vitro and ex vivo observations.
With these parameters established, the effect ofNR2BsiP infu-
sion on fear memory was evaluated. Continuous bilateral NR2B
siP infusion into rat dorsal hippocampus 24 hr prior to fearNeuron 81, 1070–1083, March 5, 2014 ª2014 Elsevier Inc. 1075
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Cdk5 Regulates NR2B in Memory Formationconditioning increased hippocampus-dependent contextual fear
memory 1.7-fold compared to scrambled peptide controls (Fig-
ure 6D). In agreement with the hippocampal-independent nature
of cue-associated fear learning (Phillips and LeDoux, 1992), no
effect was observed on tone-induced freezing. Administration
of neither NR2B siP nor scrambled control affected nociception,
pain threshold, or motor reflexes (Figures S4B and S4C). During
extinction trials, contextual memory enhancement persisted in
NR2B siP-treated rats at 48 and 72 hr after initial training (Fig-
ure S4D and S4E). The conditioned fear response was extin-
guished by 96 hr for both groups (Figure S4E). After extinction
and expiration of the mini-osmotic pump, rats were retrained.
Twenty-four hours after retraining, the contextual fear memory
was increased in rats previously infused with NR2B siP during
the initial acquisition phase, but not scrambled controls (Fig-
ure S4F), suggesting that behavioral effects persist even after
NR2B siP clearance. These data also indicate that the siP-
improvedmemorymayhavebeenmore retainedor consolidated.
The learning and memory improvements associated with
NR2B siP infusion correlated directly with reduced P-S1116
NR2B. NR2B siP infusion and fear conditioning both decreased
P-S1116 NR2B in CA1 1 hr after training (Figure S5A). Animals
that had been infused with NR2B siP and undergone fear condi-
tioning exhibited the lowest phosho-Ser1116 levels.
Previous studies found that NMDAR inhibition during the
acquisition phase impaired fear memory (Bast et al., 2003;
Zhang et al., 2008; Zhao et al., 2005). Therefore, we evaluated
whether an acute NR2B siP infusion shortly before the training
session could also improve fear memory. For this purpose,
3-month-old mice were acutely surgerized under isofluorane
anesthesia and NR2B siP was infused into dorsal hippocampus
90 min prior to fear conditioning. Acute NR2B siP infusion re-
sulted in significantly elevated freezing behavior in the context
test as compared to controls (Figure 6E). The freezing levels dur-
ing the context test of the acute paradigm were, in fact, compa-
rable to the levels observed with chronic infusion. The tone test
did not reveal any significant changes between acute peptide-
infused groups. Finally, to evaluate whether NR2B siP adminis-
tration may be a valid treatment for age-related cognitive
decline, 14-month-old mice were acutely infused with NR2B
siP and tested for fear memory (Figure S5B). As observed forFigure 4. Identification of NR2B-Cdk5 Interaction Motifs and Developm
(A) Peptide microarray of the NR2B C-terminal domain showing high (+, red) to l
(B) The cytoplasmic C terminus amino acid sequence of NR2B with potential Cd
(C) NR2B siP blocks pull-down of Cdk5 with recombinant NR2B immobilized
Immunoblots show relative levels of NR2B and Cdk5 under conditions indicated.
in plot (n = 3).
(D) Immunoblots showing that NR2B siP dose dependently inhibits in vitro phosp
has no effect.
(E) Time-dependent reduction of P-S1116 in hippocampal slices treated with NR
(Scr) control peptide (n = 4; *p < 0.05, **p < 0.01; ANOVA).
(F) NR2B siP, but not the scrambled peptide, nor CP681301 (CP) disrupts NR2B-
evaluated by coimmunoprecipitation. Cdk5 Load is also shown.
(G) NR2B cell surface levels are increased in hippocampal slices treated with NR2
control peptide (Scramble; 1 hr, 100 mM) (n = 4; **p < 0.01; ***p < 0.001; ANOVA
(H) Immunofluorescence staining of cultured hippocampal neurons for surface G
(I) Quantification of dendritic cell surface GFP-NR2B (n = 49–64 cells).
Scale bars represent 20 mm. Data are represented as mean ± SEM. See also Fig3-month-old mice, acute NR2B siP infusion 90 min prior to
training increased contextual fear memory 1.7-fold compared
to control peptide or noninfused cannulated controls. Thus,
increasing NR2B surface levels may be a suitable memory
enhancement strategy even for later stages in life. These results
are also consistent with studies showing that NR2B overexpres-
sion in forebrain neurons improves learning and memory in aged
mice (Brim et al., 2013; Cao et al., 2007).
Taken together, these findings show that selective disruption
of NR2B-Cdk5 interactions via NR2B siP enhances hippocam-
pus-dependent learning and memory through potentiation of a
regulatory mechanism that is involved in memory formation.
Thus, it is possible that thismechanism regulating NR2B function
via Cdk5 may be a suitable target for the development of cogni-
tive enhancers as therapeutics for memory impairment as well as
age-dependent cognitive decline.
DISCUSSION
In this study, we present a molecular mechanism regulating the
subcellular localization of NR2B-containing NMDAR. This mech-
anism appears to be central to synaptic transmission and
mnemonic functions and can be targeted to enhance memory.
A model of this mechanism and the effects of targeting it may
be suggested (Figure 6F). Upon glutamatergic neurotransmis-
sion, such as that occurring during synaptic plasticity induction
or memory formation, Cdk5-dependent Ser1116 phosphoryla-
tion is reduced and subsequently leads to increased cell
surface levels of NR2B-containing NMDAR. Consequently,
selective disruption of NR2B-Cdk5 interactions via the NR2B
siP increases NR2B surface levels, thereby facilitating synaptic
transmission. Intrahippocampal infusion of the NR2B siP im-
proved fear memory, suggesting that the regulation of NR2B
by Cdk5 may be a suitable target for the development of cogni-
tive enhancers.
The molecular basis of cognition is thought to involve activity-
dependent changes in intracellular signaling, gene expression,
protein synthesis, remodeling of synapses, and neurotransmis-
sion (Bibb et al., 2010). In particular, excitatory glutamatergic
neurotransmission, as well as its regulatory machinery and
downstream targets, have been singled out as central molecularent of a Small Interfering Peptide
ow (-, blue) Cdk5 binding regions.
k5 binding sites highlighted with their corresponding peptide array tiles.
on GST beads, demonstrating disruption of NR2B-Cdk5 interaction in vitro.
NR2B siP dose dependently disrupts NR2B-Cdk5 binding in vitro as depicted
horylation of Ser1116 NR2B by Cdk5, whereas the control peptide (scramble)
2B siP (25 mM) or the Cdk5 inhibitor CP681301 (CP; 50 mM), but not scrambled
Cdk5 interaction in hippocampal slices (four pooled slices for each sample) as
B siP (1 hr, 100 mM) or the Cdk5 inhibitor CP681301 (1 hr, 50 mM), but not with
). NR2B Load is also indicated.
FP-NR2B after treatment with control peptide or NR2B-siP.
ure S3.
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Figure 5. Disruption of NR2B-Cdk5 Inter-
action by NR2B siP Facilitates Synaptic
Transmission
(A) Recordings and quantification of NMDAR/
AMPAR EPSC ratio from cortical pyramidal neu-
rons treated with NR2B siP or scrambled (Scr)
control (n = 12–16).
(B and C) NMDAR EPSC sensitivity to the NR2B
inhibitor, ifenprodil, in slices incubated with NR2B
siP or scrambled control (n = 6–7).
(D and E) Extracellular CA3-CA1 field recordings in
hippocampal slices treated with NR2B siP or
control peptide (30 min, 2 mM). Sample traces of
2 min before (a) and at end (b) of siP application
and Quantitation of fEPSP slope (n = 4).
(F and G) Extracellular field recordings in hippo-
campal slices incubated with the specific NR2B
inhibitor Ro 25-6981 (3 mM) or from Cdk5 cKO
were treated with NR2B siP (30 min, 2 mM) and
quantification of fEPSP slope (n = 3) did not show a
significant effect of NR2B siP with NR2B inhibition
or in absence of Cdk5 (cKO).
Data are represented as mean ± SEM.
Neuron
Cdk5 Regulates NR2B in Memory Formationmechanisms. Signaling cascades that modulate expression,
activity, trafficking, and degradation of neurotransmitter recep-
tors are critical to the formation of memories (Chen and Roche,
2007; Lau and Zukin, 2007; Wenthold et al., 2003). Accordingly,
enhanced synaptic plasticity, learning, and memory has been
observed in several animal models that feature increased
NR2B surface levels as a result of manipulating various molecu-
lar processes including NR2B expression, trafficking, and degra-
dation (Crair and Malenka, 1995; Hawasli et al., 2007; Lee and
Silva, 2009; Tang et al., 1999; Wong et al., 2002; Yin et al.,
2011). Thus, a robust body of data singles out NR2B as a prom-
inent factor for cognitive function.
NR2B has been shown to serve as a substrate of various pro-
tein kinases (Wenthold et al., 2003). In particular, tyrosine phos-
phorylation of its extreme C terminus modulates its anchoring1078 Neuron 81, 1070–1083, March 5, 2014 ª2014 Elsevier Inc.to the postsynaptic density and may pre-
vent endocytosis. Furthermore, NR2B
has been suggested to traffic dynamically
from extra- to intrasynaptic locations on
the cell surface, possibly through associ-
ation of its extreme C terminus with dif-
ferent members of the membrane-asso-
ciated guanylate kinase (MAGUK) family.
In contrast, Ser1116 appears to reside
within a region of the cytoplasmic termi-
nus that interacts with early components
of receptor trafficking in the postsynaptic
endoplasmic reticulum (Vandenberghe
and Bredt, 2004).
Previously, Cdk5 cKOwas shown to in-
crease total NR2B levels by disrupting the
NR2B-Cdk5-calpain complex, thereby
attenuating activity-dependent degrada-
tion of NR2B by calpain (Hawasli et al.,
2007). Here, pharmacological inhibitionof Cdk5 revealed that the protein kinase also phosphorylates
NR2B, thereby modulating the activity-dependent trafficking of
the receptor to the cell surface. Thus, Cdk5 appears to have
two roles, regulating NR2B trafficking as well as metabolism.
Both these roles are probably important for synaptic plasticity
and memory, although the temporal sequence and molecular
integration of these two activity-dependent events requires
further study.
It also remains to be determined whether dephosphorylation
of Ser1116 targets NR2B selectively to the synapse or to both
synaptic and extrasynaptic compartments. As the increases in
cell surface NR2B observed here were greater than the potenti-
ation of NR2B-mediated current, it is possible that not all NR2B
driven to the surface was functional. Interestingly, other NMDAR
subunits possess endoplasmic reticulum retention motifs similar
Neuron
Cdk5 Regulates NR2B in Memory Formationto the one indicated here in NR2B. Furthermore, some of these
are also regulated via phosphorylation (Scott et al., 2001) and
in response to neuronal activity (Mu et al., 2003), suggesting a
common overall process in synaptic remodeling or homeostasis.
Numerous neurodevelopmental, neurological, and neuropsy-
chiatric disorders, such as Alzheimer’s disease, depression,
and schizophrenia, manifest cognitive deficits. Interestingly, de-
ficiencies in NMDAR trafficking have been implicated in the path-
ophysiology of many of these diseases (e.g., see Snyder et al.,
2005). Moreover, age-related cognitive decline occurs progres-
sively in all aging humans, albeit at variable rates. Although
behavioral interventions are being advanced as one group of
approaches, effective treatments to counter cognitive deficits
or memory decline are extremely limited.
Peptides are now an integral component of CNS research, and
protein-protein interactions and intracellular signaling mecha-
nisms provide a very large base of new therapeutic targets
(Jubb et al., 2012). Until recently, CNS drug discovery has
focused on developing synthetic small molecules that act pri-
marily upon targets involved in neurotransmission including re-
ceptors and ion channels. Drug target pool algorithms such as
the ‘‘rule of five’’ (Lipinski, 2000) and ‘‘the druggable genome’’
(Hopkins and Groom, 2002) have been used in an effort to facil-
itate the discovery of small molecules of high specificity for oral
delivery. However, these restrictions have often had the unin-
tended consequences of producing molecules with poor selec-
tivity and unwanted side effects. Larger molecules including
peptides and peptidomemetics that interfere with protein-pro-
tein interactions provide more contact with targets and greater
selectivity but have been limited by low bioavailability, poor
membrane permeability, and metabolic instability. These obsta-
cles are being circumvented by a number of creative means and
protein- or peptide-based drugs are now roughly 10% of the
pharmaceutical market and growing (Craik et al., 2013). As an
example of this potential, peptides that target NR2B interactions
with the postsynaptic density have been shown to neuroprotect
from ischemic injury in primates (Cook et al., 2012).
Herewedemonstratememoryenhancement by selectively tar-
geting a single phosphorylation site and NR2B-Cdk5 protein-
protein interactions with a peptide injected intracranially. It will
be interesting to find out whether further optimization in the tar-
geting of this and other synaptic mechanisms will lead to more
practical delivery modes and clinically applicable therapies.
EXPERIMENTAL PROCEDURES
Please see the Supplemental Experimental Procedures for detailed methods
on phosphorylation-site identification, phosphorylation state-specific anti-
body generation, in vitro phosphorylation, binding assays, peptide array anal-
ysis, in vivo LTP, whole-cell recordings, hippocampal cannulation, and siP
infusion.
Antibodies and Reagents
Cdk5 (C-8) and NR2A antibodies (Ab) were obtained from Santa Cruz; P-Thr75
DARPP-32, DARPP-32, and Inhibitor-1 Ab were from Cell Signaling Technol-
ogy; EGFP, FITC, and a-tubulin Ab were from Abcam; NR2B Ab was from
PhosphoSolutions; Homer-1 Ab was from Synaptic System; MAP-2 and
NeuN Ab were from Millipore; secondary anti-mouse, anti-rabbit, and anti-
goat IgG Ab were from Pierce; Cy3-conjugated anti-rabbit IgG secondary
Ab was from Jackson Immunoresearch; and Alexa 647-conjugated anti-mouse IgG secondary Ab was from Molecular Probes. P-Ser6 inhibitor-1 Ab
was previously described (Nguyen et al., 2007). The specific Cdk5 inhibitor
CP681301 was provided by Pfizer Pharmaceutical. Ifenprodil and Ro
25-6981 were from Tocris. All peptides were synthesized by the UT South-
western Protein Chemistry Technology Center utilizing the Perseptive
Biosystems Pioneer and Applied Biosystems 433 synthesizers. Peptides
were verified by mass spectrometry analysis and reversed-phase HPLC
chromatography. The sequences of the small interfering peptides (siP) were
NR2B siP, RRPPRSPDHKRYFRDKE; scrambled, RRRSYFHKEDRPPRDK;
R7 NR2B siP, RRRRRRRRPPRSPDHKRYFRDKE; R7 scrambled, RRRR
RRRRRSYFHKEDRPPRDK; Pen NR2B siP, RQIKIWFQNRRMKWKK-PPRS
PDHKRYFRDKE; and Pen control, RQIKIWFQNRRMKWKK-PPRAPDHK
RYFRDKE. The FITC tag was attached at the C terminus of the siP.
Animals
Animals were housed in a 12 hr light/dark cycle (lights on from 6:00 a.m. to
6:00 p.m.), with food and water available ad libitum. Mice in the C57BL/6
background were obtained from Jackson and were housed 3–4 per cage.
Cdk5 cKO mice were bred and maintained as previously specified (Hawasli
et al., 2007). For all experiments, age-matched male littermates were used,
unless otherwise noted. Sprague-Dawley rats were obtained from Charles
River Laboratories and bred and maintained at the UT Southwestern animal
facility. All behavioral experiments were conducted in the UTSW Rodent
Behavior Core. All experimental procedures were reviewed and approved by
the University of Texas Southwestern Institutional Animal Care and Use
Committee (IACUC).
Slice Pharmacology, Immunoprecipitation, and Cell Surface
Labeling
Hippocampal, striatal, and cortical slices were prepared as previously
described (Hawasli et al., 2007; Sahin et al., 2006; Yuen et al., 2012). Pharma-
cological treatments were performed in Mg2+-free Kreb’s buffer containing
NMDA (50 or 100 mM, 15 min), CP-681301 (5–100 mM, 60 min), or siP (0–
100 mM, 0–180 min). The R7-tagged peptides were used in slice experiments
assessing substrate phosphorylation levels. Cell surface biotinylation assays
were performed with Pierce Cell Surface Protein Isolation Kit (Thermo Scienti-
fic) according to manufacturer’s instructions. In brief, hippocampal slices were
equilibrated in ice-cold oxygenated ACSF for 5 min and then incubated for
30 min with Sulfo-NHS-SS-Biotin (0.5 mg/ml in ACSF; Pierce). Biotinylation re-
action was quenched with ACSF containing 50 mM NH4Cl and 50 mM glycine
and tissue was dissected in ice-cold dissection buffer containing protease and
phosphatase inhibitors (Plattner et al., 2006). Immunoprecipitation (IP) was
performed as previously described (Plattner et al., 2006).
Lysate Preparation and Immunoblotting
Brain dissection, tissue removal, and lysate preparation were performed with
specific emphasis on maintaining protein integrity and phosphorylation levels
by using protease and phosphatase inhibitors as described (Bibb et al., 1999;
Plattner et al., 2006). Graphs of all quantitative immunoblot analyses of
P-S1116 NR2B represent the ratio of P-S1116/total NR2B. Hippocampal sub-
field CA1 tissue including stratum radiatum, stratum pyramidale, and stratum
oriens was microdissected in ice-cold dissection buffer containing protease
and phosphatase inhibitors (Plattner et al., 2006) via a dissecting microscope.
After excision of the intact hippocampus from the brain, the dentate gyrus and
CA3 were removed longitudinally with the basal vein and the hippocampal
fissure as guidance clues.
Extracellular Field Recordings
Hippocampal slices were prepared from 3-month-old C57BL/6 mice as
described (Hawasli et al., 2007) and field excitatory postsynaptic potentials
(fEPSP) from CA1 were evoked by square current pulses (0.1 ms at
0.033 Hz) with a bipolar stimulation electrode placed at the Schaffer collat-
erals. Results were obtained with a stimulus intensity to induce 50% of the
maximal fEPSP slope. Once the baseline was stable, Pen siP or Pen control
peptides were added to the perfusion buffer for 30 min. For recordings per-
formed in the presence of the NR2B selective blocker Ro 25-6981, the Pen
siP peptide was added 10 min after starting Ro 25-6981 (3 mM) bath perfusion.Neuron 81, 1070–1083, March 5, 2014 ª2014 Elsevier Inc. 1079
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slope.
LTD analysis was performed in hippocampal slices from 16- to 17-day-old
C57BL/6 mice as previously reported (Billard, 2010; Milner et al., 2004) via
modified ACSF (in mM: 130 NaCl, 26 NaHCO3, 3 KCl, 1 MgCl2, 1.25 NaH2PO4,
2 CaCl2, 10 glucose [pH 7.4], 300 mOsm). After 15 min of stable baseline
recording, a low-frequency stimulation protocol (900 stimuli at 1 Hz) was
applied to induce LTD that was maintained for at least 1 hr. At the end of the
LTD recording, the CA1 was microdissected and homogenized in lysate buffer
containing protease and phosphatase inhibitors.
Dissociated Neuronal Cultures, Transfection, Drug Treatments, and
Live-Labeling of Cell Surface Receptors
Dissociated hippocampal neurons were prepared from P0 rats as described in
Goda and Colicos (2006) and plated onto glass coverslips coated with poly-D-
lysine (10 mg/ml) and laminin (2 mg/ml). Cultures weremaintained in Neurobasal
media (Invitrogen) supplemented with 6 mg/ml glucose, 0.1% Mito serum
extender, 2.5% B27, and 2 mM Glutamax. Hippocampal neurons were trans-
fected at DIV 7–8 by the calcium-phosphate method and used at DIV 14–18.
Constructs include pRK5-EGFP-NR2B that encodes a N-terminally EGFP-
tagged NR2B subunit (GFP-NR2B).
To evaluate the effect of Cdk5 inhibition on cell surface expression of NR2B,
neuronal cultures were treated with 25 mM CP68130 for 1 hr or with 2 mM
NR2B-siP for 30 min, 6–10 days after transfection with pRK5-EGFP-NR2B.
DMSO or control peptides were used as controls. Immunofluorescence stain-
ing of cell surface GFP-NR2Bwas performed by incubating nonpermeabilized,
live neuronal cultures with rabbit polyclonal EGFP ab (1:500, Abcam, Ab6556)
for 15min at 37C (Cingolani et al., 2008; Pozo et al., 2012). Neuronswere fixed
in PBS containing 4% paraformaldehyde and 4% sucrose for 10 min at 25C
and then permeabilized and blocked with PBS containing 10% fetal bovine
serum, 0.2%gelatine, and 0.02%Triton X-100 for 1 hr at 25C. After incubation
with mouse monoclonal Homer-1 ab (1:1,000, SYSY, 160011) for 1 hr at 25C,
neurons were washed and incubated with Cy3-conjugated anti-rabbit IgG and
Alexa 647-conjugated anti-mouse IgG for 1 hr at 25C. Cells were washed and
mounted onto microscope slides for confocal imaging. Z-stacks were
acquired with an inverted 510 Meta Zeiss confocal microscope with a 633
water objective, sequential mode, and 4 frames average. Baseline microscopy
settings were established for control cultures and maintained constant
throughout the entire imaging session. ImageJ was used to project Z-stacks
andmeasure dendritic fluorescence. Dendritic length was assessed by tracing
processes with NeuronJ and used to normalize dendritic fluorescence.
Animal Behavior
All behavior was carried out with the experimenter blind to treatment groups.
For cued fear conditioning in rats, animals were left to explore the conditioning
box (Med Associates) for 2 min, followed by a 30 s period with tone represen-
tation (90 dB, 10 kHz), which coterminated with a mild foot shock (2 s, 0.7 mA,
constant current). Rats remained in the chamber 2 min after shocking before
returning to their home cage. Conditioning boxes were thoroughly cleaned
after each animal. To test context-dependent fear memory, rats were reintro-Figure 6. Enhancement of Fear Memory by NR2B siP
(A) Immunostain of rat dorsal hippocampus infused for 24 hr with FITC NR2B siP
pyramidal neurons. Scale bars represent 250 mm and 50 mm (inset).
(B and C) Immunoblots showing infused NR2B siP versus scramble control redu
tissue punches for each condition) (C) in epifluorescent hippocampal area CA1.
(D) Experimental design and quantitation of context- and tone-elicited fearmemor
hippocampus (n = 20) showing that NR2B siP improved contextual fear memory
(E) Experimental design and quantitation of fear memory in acutely infused 3-mont
control peptide into dorsal hippocampus. Twenty-four hours later, NR2B siP-treat
Data are represented as mean ± SEM. See also Figures S4 and S5.
(F) Model of NR2B regulation via Ser1116 phosphorylation by Cdk5. At basal state
cell surface. Glutamatergic neurotransmission reduces Cdk5-dependent NR2B p
contributing tomemory formation. Addition of NR2B siP disrupts NR2B-Cdk5 inter
the cell surface, thereby enhancing memory formation.duced 24 hr after shock into the conditioning box for 5min. Freezing responses
(motionless except respirations) were recorded via a 5 s interval time-sampling
method. Twenty-seven hours after conditioning, tone-recall was assessed in a
novel context with novel odor (vanilla). The rats were left exploring the novel
context for 3 min without tone followed by a 3 min period with tone represen-
tation. Extinction of fearmemory was evaluated by re-exposing rats to the con-
ditioning box at 24, 48, 72, and 96 hr after shock for 5 min. After fear memory
extinction, rats were retrained with a 0.7 mA foot shock, and contextual
learning was analyzed 24 hr after retraining. Nociceptive response and motor
reflex were evaluated by measuring the stimulus threshold to elicit flinching,
jumping, and vocalizing in the fear conditioning paradigm and tail flick test.
For mice, cued fear conditioning was conducted in an automated system
(Med Associates) via a two conditioned stimulus (CS)-unconditioned stimulus
(US) pairings paradigm of 4 min with 60 s intertrial interval. The CS was a tone
(75 dB, 8 kHz) coterminating with a mild foot shock US (2 s, 0.7 mA, constant
current). Context-dependent conditioning was tested 24 hr later by exposing
the mice to the conditioning box for 5 min and tone-dependent freezing was
measured at 27 hr by placing the mice in a novel context with novel scent
(vanilla) for 3 min pre-CS followed by 3 min CS. Freezing responses were
assessed by computer-aided scoring as well as offline manual scoring. For
biochemistry and cell surface biotinylation, animals were sacrificed 1 hr after
fear conditioning.
Statistical Analyses
All data are represented as mean ± SEM unless stated otherwise. Statistical
analysis was performed by the Student’s t test unless stated otherwise. For
all experiments, *p < 0.05, **p < 0.01, and ***p < 0.001 were considered
significant.
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